In a recent phase Ia/b clinical trial, 41 GC/GEJC patients whose disease progressed after one or two lines of systemic therapy were treated with pembrolizumab plus ramucirumab (an IgG1 VEGFR-2 monoclonal antibody). This evidence concerns the gene KDR and gastric cancer.